Evidence map›Paper›PMID 36948369›Full record

ArticleNanomedicine : nanotechnology, biology, and medicine2023

Ligand-displaying-exosomes using RNA nanotechnology for targeted delivery of multi-specific drugs for liver cancer regression.

Satheesh Ellipilli, Hongzhi Wang, Daniel W Binzel, Dan Shu, Peixuan Guo

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine : nanotechnology, biology, and medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 42 citations in OpenAlex.

  1. [Research progress on the mechanisms and optimization strategies of mesenchymal stem cell-derived exosomes in the treatment of liver diseases].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Using aptamers for targeted delivery of RNA therapies.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Satheesh EllipilliCenter for RNA Nanobiotechnology and Nanomedicine, The Ohio State University, Columbus, OH, USA; Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, USA.
Hongzhi WangCenter for RNA Nanobiotechnology and Nanomedicine, The Ohio State University, Columbus, OH, USA; Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, USA.
Daniel W BinzelCenter for RNA Nanobiotechnology and Nanomedicine, The Ohio State University, Columbus, OH, USA; Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, USA; James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Dan ShuCenter for RNA Nanobiotechnology and Nanomedicine, The Ohio State University, Columbus, OH, USA; Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, USA; James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Peixuan GuoCenter for RNA Nanobiotechnology and Nanomedicine, The Ohio State University, Columbus, OH, USA; Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, USA; James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA; College of Medicine, The Ohio State University, Columbus, OH, USA; Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, USA. Electronic address: guo.1091@osu.edu.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · USThe Ohio State University · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3M
Optimizing RNA nanoparticles size and shape for enhancing cancer targeting and treatmentU01CA207946 · NCI · OHIO STATE UNIVERSITY · PI CARSON, WILLIAM E., GUO, PEIXUAN · 2016 to 2020
$2.7M
TNBC Ligand-displaying Exosomes Using RNA Nanotechnology for Targeted Cytosol Delivery of RNAi without Endosome EntrapmentR01CA257961 · NCI · OHIO STATE UNIVERSITY · PI BINZEL, DANIEL W, SHU, DAN · 2021 to 2025
$1.7M
NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA257961NCI NIH HHS U01 CA207946
6 · The paper itself

Abstract

Liver cancer such as hepatocellular carcinoma (HCC) poorly responds to chemotherapeutics as there are no effective means to deliver the drugs to liver cancer. Here we report GalNAc decorated exosomes as cargo for targeted delivery of Paclitaxel (PTX) and miR122 to liver tumors as an effective means to inhibit the HCC. Exosomes (Exos) are nanosized extracellular vesicles that deliver a payload to cancer cells effectively. GalNAc provides Exos targeting ability by binding to the asialoglycoprotein-receptor (ASGP-R) overexpressed on the liver cancer cell surface. A 4-way junction (4WJ) RNA nanoparticle was constructed to harbor 24 copies of hydrophobic PTX and 1 copy of miR122. The 4WJ RNA-PTX complex was loaded into the Exos, and its surface was decorated with GalNAc using RNA nanotechnology to obtain specific targeting. The multi-specific Exos selectively bind and efficiently delivered the payload into the liver cancer cells and exhibited the highest cancer cell inhibition due to the multi-specific effect of miR122, PTX, GalNAc, and Exos. The same was reflected in mice xenograft studies, the liver cancer was efficiently inhibited after systemic injection of the multi-specific Exos. The required effective dose of chemical drugs carried by Exos was significantly reduced, indicating high efficiency and low toxicity. The multi-specific strategy demonstrates that Exos can serve as a natural cargo vehicle for the targeted delivery of anticancer therapeutics to treat difficult-to-treat cancers.

Indexed as

Carcinoma, HepatocellularExosomesLiver NeoplasmsMicroRNAsAnimalsDrug CarriersHumansLigandsMicePaclitaxelDrug CarriersLigandsMicroRNAsPaclitaxel4-Way junctionDrug effluxionGalNAcLigand-displaying exosomeLiver cancer therapyMDR1miRNA 122PaclitaxelRNA-displaying exosomeRNA nanotechnology

Identifiers

PMID36948369
PMCPMC10413411
OpenAlexW4328102533

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.